SCHEMBL2565014

SCHEMBL2565014

Cc1cc(S(=O)(=O)N2CCCCC2COCC(=O)N2CCN(Cc3ccccc3)CC2)c(C)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.46
ALDH1A1 P00352 7/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
USP2 O75604 1/20 0.46
OPRM1 P35372 1/20 0.42
OPRK1 P41145 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
MAPK1 P28482 2/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 2/20 0.40
NR2F2 P24468 1/20 0.40
CYP2D6 P10635 1/20 0.39
ACHE P22303 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3828007 0.87 HCRTR1 (0.39) ALDH1A1HCRTR1HCRTR2CYP2D6
SCHEMBL3822339 0.85 HCRTR1 (0.40) HCRTR1HCRTR2MEN1KMT2A
SCHEMBL2564519 0.85 ALDH1A1 (0.50) LMNAALDH1A1SMN1; SMN2USP2OPRM1
SCHEMBL2568333 0.84 ALDH1A1 (0.44) LMNAALDH1A1SMN1; SMN2USP2THRB
SCHEMBL5128978 0.83 HCRTR1 (0.50) LMNAALDH1A1SMN1; SMN2MAPTTHRB
SCHEMBL15204129 0.83 BDKRB1 (0.45) THRBHCRTR1HCRTR2CYP2D6ACHE
SCHEMBL2569991 0.82 ALDH1A1 (0.48) LMNAALDH1A1SMN1; SMN2USP2TSHR
Hydrochloric Acid SCHEMBL2570810 0.82 BDKRB1 (0.44) THRBHCRTR1HCRTR2CYP2D6ACHE
SCHEMBL2566833 0.82 ALDH1A1 (0.43) LMNAALDH1A1SMN1; SMN2USP2OPRM1
SCHEMBL2569329 0.82 ALDH1A1 (0.44) LMNAALDH1A1SMN1; SMN2USP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066659-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2013-08-28 EP claimed
EP-2383267-A1 Substituted sulfonamide derivatives Grünenthal GmbH (DE) 2011-11-02 EP claimed
US-20100317644-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-16 US claimed
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2008-06-26 US claimed
EP-2066659-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2013-08-28 EP disclosed
US-8435978-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-05-07 US disclosed
EP-2383267-A1 Substituted sulfonamide derivatives Grünenthal GmbH (DE) 2011-11-02 EP disclosed
US-20100324009-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-23 US disclosed
US-20100317644-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-16 US disclosed
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317644-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 LMNA 2964/4885ALDH1A1 1535/4885SMN1; SMN2 45/4885
US-20100324009-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 LMNA 2964/4885ALDH1A1 1535/4885SMN1; SMN2 45/4885
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS SULT2A1, STS, SULT1A1 LMNA 2964/4885ALDH1A1 1535/4885SMN1; SMN2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.